This review assessed the long-term effects of therapies in adults with chronic asthma. The authors concluded that inhaled corticosteroids were the most effective single treatment, followed by leukotriene modifiers/receptor antagonists as second choice. If symptoms were not controlled with low-dose corticosteroids, long-acting beta2 agonists may be added. The authors' conclusions are likely to be reliable.
Two reviewers independently extracted the data using a standardised form. Any disagreements were resolved through consensus. The extracted data included the mean age of the participants and FEV1, as a percentage of the predicted or absolute volume (in litres), for each treatment comparison. For each study, the relative risks (RRs) and 95% confidence intervals (CIs) of asthma exacerbations were extracted, and absolute FEV1 values were converted into standardised effect sizes.
Methods of synthesis
How were the studies combined? The studies were combined using a random-effects model (DerSimonian and Laird) for the meta-analysis when significant statistical heterogeneity was found and a fixed-effect model in its absence (P>0.10). Pooled RRs and 95% CIs for asthma exacerbations were calculated for inhaled corticosteroids versus placebo, higher verses lower doses of inhaled corticosteroids, LABA versus placebo, and inhaled corticosteroids plus LABA versus higher dose inhaled corticosteroids.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the Cochran Q test. Pooled weighted mean differences between treatments were also calculated. Subgroup analyses were conducted for studies comparing inhaled corticosteroids with placebo to examine the influence of treatment duration, sample size and disease severity at baseline (according to FEV1). Disease severity was investigated through the comparison of higher and lower dose trials.
Results of the review
The number of studies reported in this commentary were those used in the meta-analyses of asthma exacerbation rates. Eleven RCTs (9,418 patients) compared inhaled corticosteroids with placebo. Seven RCTs (1,884 patients) compared higher dose with lower dose corticosteroids. Nine RCTs (2,854 patients) compared long-acting beta2 agonists with placebo. Ten RCTs (5,680 patients) compared combination treatment with inhaled corticosteroids plus long-acting beta2 agonists with higher dose corticosteroid therapy. Seven RCTs (4,375 patients) compared leukotriene pathway modifiers/receptor antagonists with placebo; five RCTs (2,368 patients) compared leukotriene pathway modifiers/receptor antagonists with inhaled corticosteroids. The number of patients in the four referenced studies of IgE therapy was not reported in the paper. Nineteen RCTs (3,271 patients) were used to assess the effect of treatment on FEV1.
Only the results for asthma exacerbations are reported below (the review also reported results for FEV1).
Inhaled corticosteroids: There were statistically significant reduced exacerbations with inhaled corticosteroids compared with placebo (RR 0.46, 95% CI 0.34 to 0.62; 11 trials). Statistically significant heterogeneity was detected (P<0.001). The subgroup analyses showed that risk reduction was influenced by study duration (greatest in short-term studies lasting 12 weeks), but was not influenced by sample size or disease severity at baseline (the results were reported). Higher dose of inhaled corticosteroids statistically significantly reduced exacerbations compared with lower dose therapy (RR 0.77, 95% CI 0.67 to 0.89). No statistically significant heterogeneity was detected (P=0.83).
Long-acting beta2 agonists: There were statistically significantly reduced exacerbations with long-acting beta2 agonists compared with placebo (RR 0.75, 95% CI 0.64 to 0.88; nine trials). No statistically significant heterogeneity was detected (P=0.43). The addition of long-acting beta2 agonists to inhaled corticosteroids statistically significantly reduced exacerbations compared with higher dose inhaled corticosteroids (RR 0.86, 95% CI 0.76 to 0.97; 10 trials). No statistically significant heterogeneity was detected (P=0.65).
Leukotriene pathway modifiers/receptor antagonists: There were significantly reduced exacerbations with Leukotriene pathway modifiers/receptor antagonists compared with placebo (RR 0.59, 95% CI 0.49 to 0.71; seven trials). No statistically significant heterogeneity was detected (P=0.44). They also significantly increased exacerbations compared with inhaled corticosteroids (RR 1.72, 95% CI 1.28 to 2.31; five trials). No statistically significant heterogeneity was detected (P=0.91).
Anti-immunoglobulin-E (anti-IgE): There were statistically significantly reduced exacerbations over the first 12 to 16 weeks in atopic patients with anti-IgE plus inhaled corticosteroids (see Participants Included in the Review; RR 0.55, 95% CI 0.45 to 0.66; four trials). The review did not state what the comparator treatment was. No statistically
